Quantitation of cytochrome P450 mRNAs in patients with suspected liver diseases as assessed by reverse transcriptase-polymerase chain reaction

Journal of Laboratory and Clinical Medicine

Volumn 134, Issue 2, 1999, Pages 133-140

  Finnström, Niklas ^a   Bjelfman, Catarina ^c   Thörn, Mari ^c   Lööf, Lars ^c   Rane, Anders ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; DETOXIFICATION; LIVER; MESSENGER RNA; OXIDATION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; XENOBIOTIC METABOLISM;

EID: 0033180096     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-2143(99)90117-8     Document Type: Article

References (23)

1. 1. Gonzalez FJ. Molecular genetics of the P-450 superfamily. Pharmacol Ther 1990;45:1-38.
2. 2. Nelson DR, Kamataki T, Waxman DJ, Guengerich FP, Estabrook RW, Feyereisen R, et al. The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol 1993;12:1-51.
3. 3. Watkins PB, Wrighton SA, Maurel P, Schuetz EG, Mendez-Picon G, Parker GA, et al. Identification of an inducible form of cytochrome P450 in human liver. Proc Natl Acad Sci USA 1985;82:6310-4.
4. 4. Guengerich FP, Shimada T. Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chem Res Toxicol 1991;4:391-407.
5. 5. Murray M. P450 enzymes: inhibition mechanisms, genetic regulation and effects of liver disease. Clin Pharmacokinet 1992;23:132-46.
6. 6. Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977;2:584-6.
7. 7. de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994;269:15419-22.
8. 8. Guengerich FP. Polymorphism of cytochrome P-450 in humans. Trends Pharmacol Sci 1989;10:107-9.
9. 9. Tucker GT. Clinical implications of genetic polymorphism in drug metabolism. J Pharm Pharmacol 1994;46(suppl 1):417-24.
10. 10. Gough AC, Miles JS, Spurr NK, Moss JE, Gaedigk A, Eichelbaum M, et al. Identification of the primary gene defect at the cytochrome P450 CYP2D locus. Nature 1990;347:773-6.
11. 11. Gonzalez FJ, Idle JR. Pharmacogenetic phenotyping and genotyping: present status and future potential. Clin Pharmacokinet 1994;26:59-70.
12. 12. Finnström N, Thörn M, Bjelfman C, Lööf L, Rane A. Varying cytochrome P450 specific mRNA levels in liver disease as assessed in needle biopsies. First Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT), Paris, France, September 27-30, 1995.
13. 13. Vanden Heuvel JP, Tyson FL, Bell DA. Construction of recombinant RNA templates for use as internal standard in quantitative RT-PCR. Biotechniques 1993;14:395-8.
14. 14. Gilliland G, Perrin S, Blanchard K, Bunn HF. Analysis of cytokine mRNA and DNA: detection and quantitation by competitive polymerase chain raction. Proc Natl Acad Sci USA 1990;87:2725-9.
15. 15. Vanden Heuvel JP, Clark GC, Thompson CL, McCoy Z, Miller C, Lucier GW, et al. CYP1A1 mRNA levels as human exposure biomarker: use of quantitative polymerase chain reaction to measure CYP1A1 expression in human peripheral blood lymphocytes. Carcinogenesis 1993;14:2003-6.
16. 16. Durnam DM, Palmitier RD. A practical approach for quantitating specific mRNAs by solution hybridization. Anal Biochem 1983;131:385-93.
17. 17. Melton DA, Krieg PA, Rebagliati MR, Maniatis T, Zinn K, Green MR. Efficient in vitro synthesis of biologically active RNA and RNA hybridization probes from plasmids containing a bacteriophage SP6 promoter. Nucleic Acids Res 1984;12:7035-56.
18. 18. Rane A, Bjelfman C, Thyr C, Porsch-Hällström I. Opiatespecific effects on mRNA and catalytic activity of a hepatic cytochrome P450 isozyme. Regul Pept 1994;1(suppl):273-8.
19. 19. Andersen MRF, Farin FM, Omiencinski CJ. Quantification of multiple human cytochrome P450 mRNA molecules using competitive reverse transcriptase-PCR. DNA Cell Biol 1998;17:231-8.
20. 20. Schweikl H, Taylor JA, Kitareewan S, Linko P, Nagorney D, Goldstein JA. Expression of CYP1A1 and CYP1A2 genes in human liver. Pharmacogenetics 1993;3:239-49.
21. 21. George J, Liddle C, Murray M, Byth K, Farrell GC. Pretranslational regulation of cytochrome P450 genes is responsible for disease-specific changes of individual P450 enzymes among patients with chirrosis. Biochem Pharmacol 1995;49:873-81.
22. 22. Ingelman-Sundberg M, Johansson I, Terelius Y, Eliasson E, Ekström G, Buhler R, et al. Ethanol-inducible CYP2E1: toxicological importance and regulation by nutrients. In: Parke DV, Ioannides C, Walker R, editors. Food, nutrition and chemical toxicity. London: Smith-Gordon; 1993. p. 149-60.
23. 23. Hakkola J, Pasanen M, Purkunen R, Saarikoski S, Pelkonen O, et al. Expression of xenobiotic-metabolizing cytochrome P450 forms in human adult and fetal liver. Biochem Pharmacol 1994;48:59-64. clnes that require accurate sampling of excreted organisms. (J Lab Clin Med 1999;134:141-46)